Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 49.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 620 shares of the specialty pharmaceutical company’s stock after buying an additional 206 shares during the quarter. GAMMA Investing LLC’s holdings in Jazz Pharmaceuticals were worth $76,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after purchasing an additional 704 shares during the period. Versant Capital Management Inc boosted its holdings in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 350 shares in the last quarter. Finally, Signaturefd LLC boosted its stake in shares of Jazz Pharmaceuticals by 273.4% during the 3rd quarter. Signaturefd LLC now owns 1,516 shares of the specialty pharmaceutical company’s stock worth $169,000 after acquiring an additional 1,110 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on JAZZ. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $177.00.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $121.41 on Friday. The stock’s 50 day moving average price is $122.02 and its 200 day moving average price is $114.06. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $7.34 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the sale, the chief executive officer now owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 8,253 shares of company stock valued at $1,001,434. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.